PMID- 37233496 OWN - NLM STAT- MEDLINE DCOM- 20230529 LR - 20240109 IS - 1660-3397 (Electronic) IS - 1660-3397 (Linking) VI - 21 IP - 5 DP - 2023 May 17 TI - Fucoidan from Fucus vesiculosus Inhibits Inflammatory Response, Both In Vitro and In Vivo. LID - 10.3390/md21050302 [doi] LID - 302 AB - Fucoidan has been reported to present diverse bioactivities, but each extract has specific features from which a particular biological activity, such as immunomodulation, must be confirmed. In this study a commercially available pharmaceutical-grade fucoidan extracted from Fucus vesiculosus, FE, was characterized and its anti-inflammatory potential was investigated. Fucose was the main monosaccharide (90 mol%) present in the studied FE, followed by uronic acids, galactose, and xylose that were present at similar values (3.8-2.4 mol%). FE showed a molecular weight of 70 kDa and a sulfate content of around 10%. The expression of cytokines by mouse bone-marrow-derived macrophages (BMDMs) revealed that the addition of FE upregulated the expression of CD206 and IL-10 by about 28 and 22 fold, respectively, in respect to control. This was corroborated in a stimulated pro-inflammatory situation, with the higher expression (60 fold) of iNOS being almost completely reversed by the addition of FE. FE was also capable of reverse LPS-caused inflammation in an in vivo mouse model, including by reducing macrophage activation by LPS from 41% of positive CD11C to 9% upon fucoidan injection. Taken together, the potential of FE as an anti-inflammatory agent was validated, both in vitro and in vivo. FAU - Wang, Lingzhi AU - Wang L AD - School of Biotechnology and Health Sciences, Wuyi University, Jiangmen 529000, China. FAU - Oliveira, Catarina AU - Oliveira C AD - 3B's Research Group, I3Bs-Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciencia e Tecnologia, Zona Industrial da Gandra, Barco, 4805-017 Guimaraes, Portugal. AD - ICVS/3B's-PT Government Associate Laboratory, Braga, 4710-057 Guimaraes, Portugal. FAU - Li, Qiu AU - Li Q AD - State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China. FAU - Ferreira, Andreia S AU - Ferreira AS AUID- ORCID: 0000-0002-0321-2207 AD - LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, Campus de Santiago, 3810-193 Aveiro, Portugal. FAU - Nunes, Claudia AU - Nunes C AUID- ORCID: 0000-0001-7217-2790 AD - CICECO, Department of Chemistry, University of Aveiro, Campus de Santiago, 3810-193 Aveiro, Portugal. FAU - Coimbra, Manuel A AU - Coimbra MA AUID- ORCID: 0000-0001-8898-6342 AD - LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, Campus de Santiago, 3810-193 Aveiro, Portugal. FAU - Reis, Rui L AU - Reis RL AUID- ORCID: 0000-0002-4295-6129 AD - 3B's Research Group, I3Bs-Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciencia e Tecnologia, Zona Industrial da Gandra, Barco, 4805-017 Guimaraes, Portugal. AD - ICVS/3B's-PT Government Associate Laboratory, Braga, 4710-057 Guimaraes, Portugal. FAU - Martins, Albino AU - Martins A AUID- ORCID: 0000-0003-3868-0251 AD - 3B's Research Group, I3Bs-Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciencia e Tecnologia, Zona Industrial da Gandra, Barco, 4805-017 Guimaraes, Portugal. AD - ICVS/3B's-PT Government Associate Laboratory, Braga, 4710-057 Guimaraes, Portugal. FAU - Wang, Chunming AU - Wang C AD - State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China. FAU - Silva, Tiago H AU - Silva TH AUID- ORCID: 0000-0001-8520-603X AD - 3B's Research Group, I3Bs-Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciencia e Tecnologia, Zona Industrial da Gandra, Barco, 4805-017 Guimaraes, Portugal. AD - ICVS/3B's-PT Government Associate Laboratory, Braga, 4710-057 Guimaraes, Portugal. FAU - Feng, Yanxian AU - Feng Y AD - School of Biotechnology and Health Sciences, Wuyi University, Jiangmen 529000, China. AD - State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China. LA - eng GR - "ATLANTIDA", NORTE-01-0145-FEDER-000040/Norte 2020/ GR - 0474_BLUEBIOLAB_1_E/INTERREG Espana-Portugal 2014-2020/ GR - UIDB/50011/2020/Fundacao para a Ciencia e Tecnologia/ GR - UIDP/50011/2020/Fundacao para a Ciencia e Tecnologia/ GR - LA/P/0006/2020/Fundacao para a Ciencia e Tecnologia/ GR - UIDB/50006/2020/Fundacao para a Ciencia e Tecnologia/ GR - SFRH/BD/102471/2014/Fundacao para a Ciencia e Tecnologia/ GR - 32000936/National Natural Science Foundation of China/ PT - Journal Article DEP - 20230517 PL - Switzerland TA - Mar Drugs JT - Marine drugs JID - 101213729 RN - 9072-19-9 (fucoidan) RN - 0 (Lipopolysaccharides) RN - 0 (Polysaccharides) RN - 0 (Cytokines) SB - IM MH - Mice MH - Animals MH - *Fucus MH - Lipopolysaccharides MH - Polysaccharides/pharmacology MH - Cytokines PMC - PMC10221219 OTO - NOTNLM OT - Fucus vesiculosus OT - anti-inflammatory OT - fucoidan OT - macrophage COIS- The authors declare no conflict of interest. EDAT- 2023/05/26 13:09 MHDA- 2023/05/29 06:41 PMCR- 2023/05/17 CRDT- 2023/05/26 10:13 PHST- 2022/10/21 00:00 [received] PHST- 2023/05/08 00:00 [revised] PHST- 2023/05/10 00:00 [accepted] PHST- 2023/05/29 06:41 [medline] PHST- 2023/05/26 13:09 [pubmed] PHST- 2023/05/26 10:13 [entrez] PHST- 2023/05/17 00:00 [pmc-release] AID - md21050302 [pii] AID - marinedrugs-21-00302 [pii] AID - 10.3390/md21050302 [doi] PST - epublish SO - Mar Drugs. 2023 May 17;21(5):302. doi: 10.3390/md21050302.